The U.S. Meals and Drug Administration (FDA) has granted quick observe designation to the investigational remedy MNV-201 for the therapy of myelodysplastic...
The U.S. Meals and Drug Administration (FDA) granted approval to Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) on Sept. 19, 2025, for subcutaneous...
